Germany’s Liver Disease Therapeutics market size stood at around USD XX.X billion in 2019 and is projected to reach USD XX.X billion by 2028, exhibiting a CAGR of 11% during the forecast period.
The percentage of the aged population diagnosing with liver-related diseases is significantly increasing is primarily driving the growth of the German liver disease therapeutics market. Within Europe, Germany accounts for the largest liver disease treatment market share.
Factors like increasing reimbursement policies for liver diseases, the government, and other organizations bringing awareness in public by conducting liver disease programs have acted as a catalyst for the growth of this market.
Market Driving and Restraining Factors
The driving factors for the growth of the liver disease therapeutics market in Germany include the excess intake of over-the-counter high dosage drugs, reimbursement policies for liver diseases in the healthcare sector, government, and other private organizations bring out the awareness by organizing programs regarding liver disease treatment which propels the market during the analysis period.
Growth in the liver disease therapeutics market can also be further attributed to various technological advancements in imaging techniques, a Y-O-Y increase in the patients diagnosing with liver disease, and an increasing number of mergers and acquisitions that are happening between the companies. The license expiration of a few drugs and robust pipeline drugs for the treatment of liver diseases is adding fuel to the market.
Strict regulations in approving the new drugs, and high costs required for the development of new drugs, and the high costs associated with the treatment for liver diseases are expected to hamper the market growth to a specific limit.